small molecule

ONUREG

AZACITIDINE

Loss of exclusivityJune 2030latest FDA-listed patent expiry

CompanyBRISTOL MYERS SQUIBB CO

Drug detail

Brand name	ONUREG
Active ingredient	AZACITIDINE
Strength	300MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	September 2020
Marketing status	RX

Listed patents

Patent	Expires	Type
8846628	June 2030	product
12053482	May 2029	use U-2950
11571436	May 2029	product

Regulatory exclusivity

Code	Expires
ODE-320	September 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from BRISTOL MYERS SQUIBB CO